A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Trial details
- Registry ID
- NCT07128550
- Drugs studied
- Bulevirtide, Elebsiran, Tobevibart
TrialRedline tracks 9 clinical trials sponsored by Vir Biotechnology, Inc.: 3 Phase 3, 5 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 | Bulevirtide, Elebsiran, Tobevibart | Active not recruiting | 2026-12Estimated |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338 | Elebsiran, Tobevibart | Active not recruiting | 2026-09-30Actual |
| Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.NCT04913675 | Sotrovimab, sotrovimab | Terminated | 2022-07-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.NCT05461170 | NRTI, VIR-2218, VIR-3434 | Active not recruiting | 2031-11Estimated |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 | Bulevirtide, Elebsiran, Tobevibart | Active not recruiting | 2029-03Estimated |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionNCT04856085 | PEG-IFNα, VIR-2218, VIR-3434 | Completed | 2026-03-16Actual |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionNCT04412863 | VIR-2218, pegylated interferon-alfa 2a | Completed | 2024-03-25Actual |
| A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza ANCT05567783 | VIR-2482 (1200 mg), VIR-2482 (450 mg) | Terminated | 2023-05-05Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersNCT05356741 | VIR-5818, pembrolizumab | Recruiting | 2028-04Estimated |
Names as written in the registry records.
NCT07142811 · Vir Biotechnology, Inc.
Before: Nov 2026. After: Mar 2029.
NCT06903338 · Vir Biotechnology, Inc.
Before: Estimated. After: Actual.
Before: 31 Dec 2026. After: 30 Sep 2026.
NCT07128550 · Vir Biotechnology, Inc.
Before: Recruiting. After: Active not recruiting.
NCT05461170 · Vir Biotechnology, Inc.
Before: Aug 2029. After: Nov 2031.
NCT04856085 · Vir Biotechnology, Inc.
Before: Estimated. After: Actual.
Before: Mar 2026. After: 16 Mar 2026.
Before: Active not recruiting. After: Completed.
NCT07142811 · Vir Biotechnology, Inc.
Before: Recruiting. After: Active not recruiting.